. 2022 Jan 10;27(1):e12866. doi: 10.1111/hel.12866

TABLE 4.

Seropositivity of Helicobacter spp. in patients who tested negative for H. pylori with the commercial serological test

	Biliary tract cancer group (N = 20)	Pancreatic cancer group (N = 37) ^a	Control group (N = 13)
Positive for anti‐H. bilis antibodies	3 ^b	15.0	10 ^b	27.0	0	‐
Positive for anti‐H. hepaticus antibodies	2	10.0	6	16.2	0	‐

Biliary tract cancer group (N = 20)

Pancreatic cancer group (N = 37) ^a

Control group

(N = 13)

Positive for anti‐H. bilis antibodies

3 ^b

15.0

10 ^b

27.0

‐

Positive for anti‐H. hepaticus antibodies

10.0

16.2

‐

ELISA was performed using Helicobacter spp.‐specific whole‐cell antigens.

Cutoff values of seropositivity: 0.797 for anti‐H. bilis antibodies, 0.598 for anti‐H. hepaticus antibodies

All other between‐group comparisons were statistically nonsignificant.

^{^a}

p = 0.046 for the comparison of seropositivity for anti‐H. bilis antibodies between the pancreatic cancer group and the control group.

^{^b}

In the 13 cases that were negative for anti‐H. pylori antibodies but positive for anti‐H. bilis antibodies, 8 were also positive for anti‐H. hepaticus antibodies.